Wegovy Side Effects: The Complete 2026 Guide (Semaglutide for Weight Loss, by the Numbers)

TL;DR

Wegovy is semaglutide — the same molecule as Ozempic — dosed higher (2.4 mg weekly) and FDA-approved specifically for chronic weight management. In the pivotal STEP-1 trial (Wilding et al., NEJM 2021, n=1,961), 74.2% of Wegovy patients reported gastrointestinal side effects vs 47.9% on placebo. The most common: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%). Because Wegovy's dose is 20% higher than Ozempic's top Type 2 diabetes dose, side-effect incidence is consistently higher. The bigger story, though, is long-term: after stopping Wegovy, the STEP-1 extension trial found patients regained two-thirds of their lost weight within one year. This guide covers every Wegovy side effect by the numbers, why they happen, when they stop, and the evidence-based ways to reduce them — including what to do about muscle loss, hair thinning, and "Wegovy face."

Key Takeaways

• Wegovy = semaglutide 2.4 mg/week — the same drug as Ozempic, at a higher dose, approved for chronic weight management (not diabetes).
• Higher dose = more side effects. In STEP-1, nausea hit 44% of Wegovy patients vs ~20% at Ozempic's 1 mg dose in SUSTAIN trials.
• Most GI side effects appear in weeks 1–2 of each dose escalation and fade by week 12 at the maintenance dose — but each step up (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) resets the clock.
• FDA-recognized serious risks (2022 label update): pancreatitis, gallbladder disease, thyroid C-cell tumors (boxed warning), severe dehydration from GI loss, worsening diabetic retinopathy.
• Fat-free mass loss is real. Prado et al. (Lancet D&E 2024) found 25–39% of weight lost on semaglutide is lean mass — muscle, organ, and bone.
• Weight regain after stopping is the signature long-term problem. STEP-4 data: patients regain two-thirds of lost weight within a year.
• Side effects can be reduced with dose patience, protein-first meals, electrolyte hydration, fiber, ginger, and targeted supplementation.

What Is Wegovy, Exactly?

Wegovy is the brand name for semaglutide 2.4 mg, a once-weekly injectable GLP-1 receptor agonist from Novo Nordisk. It was FDA-approved in June 2021 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, and in December 2022 expanded for adolescents 12 and older.

Chemically, Wegovy is identical to Ozempic — both are semaglutide. The difference is dose and label:

• Ozempic: approved for Type 2 diabetes; maximum dose 2.0 mg/week (most prescriptions end at 1.0 mg).
• Wegovy: approved for weight management; maintenance dose 2.4 mg/week (20% higher).
• Rybelsus: oral semaglutide, also for Type 2 diabetes.

Semaglutide mimics the gut hormone GLP-1, which slows gastric emptying, suppresses appetite via the brain's hypothalamus, and enhances glucose-dependent insulin secretion. The weight loss is real — STEP-1 showed a mean 14.9% body weight reduction at 68 weeks. So are the side effects.

The frame for this entire guide: Wegovy is Ozempic dosed up for weight loss. Higher dose = bigger appetite suppression = more GI disruption = more side effects. If you've read about Ozempic, add roughly 20–40% to every number.

Why Wegovy Causes More Side Effects Than Ozempic

GLP-1 side effects are dose-dependent. This is mechanistically straightforward: the higher the dose, the more receptor activation across the gut, brain, and pancreas — and the more gastric emptying slows, which drives nausea and vomiting.

Compare the trials:

• SUSTAIN-6 (semaglutide 0.5 mg and 1.0 mg for T2D): nausea 11.4–16.3%, vomiting 5.7–8.4%.
• STEP-1 (semaglutide 2.4 mg for weight loss): nausea 44.2%, vomiting 24.8%.

Same molecule, higher dose, dramatically more GI effect. The FDA prescribing information for Wegovy explicitly states that adverse events "were mostly GI-related, mild to moderate, and transient," but the incidence numbers are what they are.

This is why Wegovy uses a 16-week dose escalation schedule (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg, each step for 4 weeks). The slow ramp is designed to let your gut adapt before the next dose increase.

The Side Effects, Ranked by Frequency

All incidence figures below are from the Wegovy FDA prescribing information and the STEP-1 pivotal trial (Wilding et al., NEJM 2021, n=1,961 adults without Type 2 diabetes). Numbers reflect Wegovy 2.4 mg vs placebo over 68 weeks.

1. Nausea — 44.2% (vs 16.1% placebo)

By far the most common Wegovy side effect. Onset is typically within the first 48 hours of your first injection, peaks in week 2, and generally resolves within 1–2 weeks at each maintenance dose. About 6% of STEP-1 patients discontinued Wegovy due to GI side effects — nausea was the top driver. (See our full nausea tactics guide — the same playbook applies to Wegovy.)

2. Diarrhea — 31.5%

Driven by altered gut motility and bile-acid handling. Usually mild, but can cause dehydration if persistent. More than 3 watery stools/day for more than 48 hours warrants a doctor call.

3. Vomiting — 24.8%

Often follows nausea — meal size is the biggest trigger. Smaller, protein-first meals reduce incidence dramatically. Persistent vomiting plus inability to keep fluids down is a medical emergency (risk of acute kidney injury from dehydration, which FDA has specifically flagged).

4. Constipation — 23.4%

The counterintuitive one: semaglutide slows everything, including the colon. Fiber intake, hydration, and movement all help. If constipation goes beyond 3 days or is painful, see our constipation remedies guide.

5. Abdominal Pain — 20.0%

Usually diffuse, cramping. New, severe, persistent, or radiating-to-the-back pain is different — that pattern can indicate pancreatitis (see serious side effects section).

6. Headache — 14.2%

Often dehydration-driven. Electrolytes + consistent water intake resolve most cases.

7. Fatigue — 11.2%

The Reddit-famous "Wegovy fatigue" is well-documented in trial data. Driven by reduced caloric intake, possible micronutrient deficits (B12, iron, magnesium), muscle loss, and sleep disruption from GI symptoms. See our GLP-1 nutrient deficiency guide.

8. Dyspepsia (Indigestion) — 9.2%

Bloating, reflux, early satiety. The "feels full after three bites" effect of semaglutide is largely this.

9. Injection-Site Reactions — 8.0%

Redness, itching, small bruising. Rotate sites (abdomen, thigh, upper arm) and let the pen come to room temperature before injecting.

10. Hair Loss / Thinning — 3.0% in STEP-1, higher in real-world reports

STEP-1 recorded alopecia at 3% vs 1% placebo. Real-world and post-marketing data suggest substantially higher rates — FDA has acknowledged this in post-marketing surveillance. The mechanism is telogen effluvium from rapid weight loss and low-protein intake, not the drug itself attacking follicles. Full breakdown in our GLP-1 hair loss guide.

11. Muscle Loss / Fat-Free Mass Loss

Not listed as a traditional "side effect" on the label, but arguably the most consequential long-term issue. Prado et al. (Lancet D&E 2024) found that 25–39% of the weight lost on semaglutide is fat-free mass — muscle, organ tissue, and bone. For a patient losing 30 pounds, that's 7.5–11.5 pounds of lean mass. See our muscle-loss prevention protocol.

Wegovy vs Ozempic Side Effects

Same drug, different doses, different approved uses. Here's the head-to-head. Wegovy figures from the FDA prescribing information and STEP-1 (semaglutide 2.4 mg). Ozempic figures from the FDA prescribing information and SUSTAIN trials (semaglutide 1.0 mg, the most common maintenance dose).

Takeaway: Wegovy roughly doubles the GI side-effect rate of Ozempic at its typical maintenance dose. That's the cost of the extra weight-loss efficacy. For a deeper look at the lower-dose version, see our Ozempic side effects guide. For the tirzepatide (Mounjaro/Zepbound) alternative, see our Mounjaro side effects guide.

Serious Side Effects: When to Call Your Doctor

The common side effects above are uncomfortable but not dangerous for most people. These are the ones that warrant immediate medical attention.

Pancreatitis

Severe, persistent abdominal pain — often radiating to the back — sometimes with vomiting. The FDA label requires discontinuation if pancreatitis is suspected. STEP-1 reported acute pancreatitis in 0.2% of Wegovy patients vs 0 on placebo.

Gallbladder Disease (Added to Label 2022)

In March 2022, the FDA updated the Wegovy label to include a warning for cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation). STEP-1 found gallbladder disorders in 2.6% of Wegovy patients vs 1.2% on placebo. Rapid weight loss is itself a gallstone risk factor, which Wegovy amplifies.

Thyroid C-Cell Tumors (Boxed Warning)

Wegovy carries a boxed warning — the FDA's most serious warning — for thyroid C-cell tumors, based on rodent studies. Human relevance is unknown, but the label contraindicates Wegovy in patients with personal or family history of medullary thyroid carcinoma or MEN-2 syndrome.

Severe Dehydration and Acute Kidney Injury

Post-marketing reports of acute kidney injury, often reversible, in patients with severe vomiting/diarrhea. This is the most common "ER visit" scenario — usually avoidable with electrolytes and slow dose escalation.

Worsening Diabetic Retinopathy (Diabetics Only)

In diabetics, rapid glucose lowering can transiently worsen retinopathy. SUSTAIN-6 flagged this in patients with pre-existing retinopathy. Less relevant for non-diabetic Wegovy users, but worth knowing.

Hypoglycemia

Low risk as monotherapy; meaningful risk when combined with insulin or sulfonylureas.

Suicidal Ideation (Under FDA Review)

In 2024 the FDA completed a review of post-marketing reports and did not find a causal link, but the label retains a monitoring recommendation. Report new mood changes to your prescriber.

The STEP-1 Weight Regain Problem

This is the Wegovy story that doesn't get enough airtime.

The STEP-1 extension trial (Rubino et al., JAMA 2021) followed patients who had completed 68 weeks on Wegovy. Participants were randomized to either continue Wegovy or switch to placebo. The result:

• Patients who stayed on Wegovy continued losing modestly more weight.
• Patients who stopped Wegovy regained two-thirds of their lost weight within 1 year, and most of the metabolic improvements (blood pressure, lipids, glycemic markers) reversed alongside it.

The mechanism is straightforward: GLP-1 agonists work as long as they're bound to receptors. Stop the drug, appetite returns, gastric emptying normalizes, and the underlying physiology of obesity reasserts itself. The brain's "defended body weight" set point doesn't permanently shift.

This is why Wegovy is positioned as a chronic medication — not a 6-month intervention. But cost, shortages, insurance denials, and side-effect fatigue push many users to stop, and the STEP-1 extension is a preview of what happens next. We cover the mitigation playbook in detail in our post-GLP-1 weight regain prevention guide — the same physiology applies to Wegovy and arguably hits harder because starting weight loss was larger.

The Side Effects People Don't Talk About

The FDA label covers the clinical trial adverse events. These are the ones that dominate Reddit, TikTok, and real-world practice.

"Wegovy Face" (Faster Than Ozempic Face)

Rapid fat loss in facial compartments — buccal fat, temporal fat, peri-orbital — producing a gaunt, prematurely aged look. It's the same phenomenon as "Ozempic face" but typically appears faster on Wegovy because weight loss is faster (mean 14.9% in STEP-1 vs ~6% on Ozempic 1 mg). Collagen synthesis, protein intake, and pace of weight loss all matter. Full protocol: Ozempic face prevention guide.

Hair Thinning (Telogen Effluvium)

As noted above, STEP-1 reported 3% but real-world rates are materially higher. Shedding typically begins 2–4 months into treatment, peaks around month 6, and resolves once weight stabilizes and protein intake is adequate. Biotin alone is insufficient — the cause is nutritional, not cosmetic.

Muscle and Bone Loss

Prado et al. (2024) and the American College of Lifestyle Medicine / American Society for Nutrition 2025 joint advisory both flag fat-free mass loss as the under-discussed long-term risk of GLP-1 therapy. Loss of skeletal muscle reduces resting metabolic rate (making post-drug weight regain worse), and bone-density loss is a concern especially in post-menopausal women.

"Wegovy Fatigue"

The Reddit phenomenon has a physiologic basis: low caloric intake + low protein intake + reduced micronutrient absorption + GI-driven sleep disruption + muscle loss. It's not the drug directly — it's the nutritional deficit the drug creates if you don't actively eat against it.

Food Noise Returns When You Stop

The quieting of "food noise" is one of the most-reported subjective wins on Wegovy. It's also temporary — food noise returns within weeks of discontinuation, often louder than before, which is part of why weight regain is so consistent.

Timeline: When Do Wegovy Side Effects Start and Stop?

Because Wegovy uses a 16-week dose escalation (five steps, four weeks each), the side-effect timeline repeats itself at each step up.

Week 1 (Starting Dose 0.25 mg)

First injection. Nausea can begin within 24–48 hours. Mild appetite suppression noticeable within 3–5 days.

Week 2

GI symptoms usually peak. Nausea, occasional vomiting, reduced food intake. Most users describe this as the hardest week of any dose step.

Weeks 3–4

Adaptation. GI symptoms typically fade to a low baseline before the next dose increase.

Each Dose Step (0.5, 1.0, 1.7, 2.4 mg)

The cycle repeats. Week 1–2 of each new dose is symptom-heavy; weeks 3–4 are adaptation. Your prescriber can hold you at a lower dose longer if tolerability is poor.

Month 4 Onward (Maintenance at 2.4 mg)

By week 12 at the full maintenance dose, most patients have reached a stable tolerability plateau. GI symptoms are present but low-grade. Hair-thinning timeline typically runs months 3–7.

If You Stop

Side effects fade within 2–3 weeks (semaglutide half-life is ~1 week — full washout takes ~5 weeks). Appetite, food noise, and weight regain follow the STEP-1 extension pattern above.

How to Reduce Wegovy Side Effects

The evidence-based playbook — from clinical guidelines, GI specialists, and the ACLM/ASN 2025 advisory.

1. 1.Stay at each dose escalation step longer if needed. The 4-week schedule is a minimum, not a maximum. Extending to 6–8 weeks is a clinically accepted strategy for poor tolerability.
2. 2.Eat small, protein-first meals. Target 1.0–1.6 g protein per kg body weight daily. Start every meal with protein — this reduces post-meal nausea meaningfully.
3. 3.Avoid fatty, fried, and high-sugar foods. These delay gastric emptying further and are the #1 trigger for post-meal vomiting.
4. 4.Hydrate with electrolytes, not just water. Plain water doesn't replace the sodium/potassium lost to GI symptoms. Low-sugar electrolyte mixes are ideal.
5. 5.Fiber for constipation. Soluble fiber (psyllium, oats) plus gradual dose increase. Aim for 25–35 g/day.
6. 6.Ginger for nausea. Meta-analyses support 1–2 g/day of ginger for drug-induced nausea. Capsules, tea, or real ginger all work.
7. 7.Protein + resistance training for muscle preservation. Two to three resistance sessions per week is the evidence-based floor for attenuating lean-mass loss during caloric deficit.
8. 8.Vitamin B12, iron, magnesium, vitamin D screening. Low caloric intake predictably creates micronutrient gaps — get a baseline panel. See our supplements to take on GLP-1s guide.
9. 9.Adequate sleep. Poor sleep amplifies every side effect and sabotages muscle preservation.
10. 10.Inject at night, not morning. Clinical lore with real support — sleeping through the first 12–24 hours of peak GI effect is more tolerable than working through it.

Supplement Protocol for Wegovy Users

Nutritional gaps are the mechanism behind most of Wegovy's "non-label" side effects — hair thinning, fatigue, muscle loss, "Wegovy face." The ACLM/ASN 2025 advisory explicitly recommends targeted supplementation during GLP-1 therapy because caloric intake is too low to meet RDAs from food alone for many users.

Supplements don't replace the drug's effect — they replace the nutrients you're no longer getting from food. Take our GLP-1 quiz for a personalized stack recommendation based on your dose, weight loss rate, and symptoms.

Frequently Asked Questions

Are Wegovy side effects worse than Ozempic side effects?

Yes, on average. Wegovy (semaglutide 2.4 mg) roughly doubles the incidence of the most common GI side effects compared to Ozempic at its typical maintenance dose (1.0 mg). In STEP-1, nausea hit 44% on Wegovy vs 20% on Ozempic in SUSTAIN trials. The drug is identical — the difference is dose.

Do Wegovy side effects go away?

Most GI side effects peak in weeks 1–2 of each dose step and fade within 2–4 weeks as your gut adapts. Reaching the full maintenance dose of 2.4 mg and staying there for about 12 weeks typically produces a stable, low-level baseline. Long-term effects — hair thinning, muscle loss, "Wegovy face" — follow a different timeline and require active management with nutrition and training.

Why is Wegovy making me so tired?

"Wegovy fatigue" is real and documented in trial data (11.2% in STEP-1). The causes are nutritional, not pharmacologic: low calorie intake, inadequate protein, micronutrient gaps (B12, iron, magnesium), muscle loss, and GI-disrupted sleep. A baseline nutrient panel, protein-first meals, and basic supplementation usually resolve it. Full breakdown: our GLP-1 nutrient deficiency guide.

Can Wegovy cause hair loss?

Yes — about 3% in the STEP-1 trial, higher in real-world reports. The mechanism is telogen effluvium triggered by rapid weight loss and low protein intake, not the drug itself attacking follicles. Shedding usually starts 2–4 months in, peaks around month 6, and resolves once weight stabilizes and protein intake is restored. Prevention is protein-first, iron and ferritin screening, and collagen/biotin support.

What happens if I stop Wegovy?

You regain most of the weight. The STEP-1 extension (Rubino et al., JAMA 2021) found patients regained two-thirds of their lost weight within one year of discontinuation, and most metabolic improvements reversed. This is why GLP-1s are positioned as chronic therapy. Full mitigation playbook: our post-GLP-1 weight regain prevention guide.

Does Wegovy cause muscle loss?

Yes. Prado et al. (Lancet D&E 2024) found 25–39% of the weight lost on semaglutide is fat-free mass — muscle, organ tissue, and bone. Prevention requires 1.0–1.6 g/kg protein daily plus resistance training 2–3 times per week. This is one of the under-discussed long-term risks. See our Wegovy/Ozempic muscle-loss prevention protocol.

How long does Wegovy stay in your system?

Semaglutide has a half-life of approximately 1 week. Full washout after your last dose takes about 5 weeks. Side effects generally fade within 2–3 weeks of stopping; appetite and food noise return within a similar window.

Can I take Wegovy if I've had gallbladder problems?

Discuss with your prescriber. The FDA added a gallbladder-disease warning to the Wegovy label in 2022 based on increased incidence in trials. If you have a history of gallstones or cholecystitis, the risk–benefit calculation changes.

Is Wegovy safe long-term?

The longest rigorous safety data we have is from the SELECT trial (Lincoff et al., NEJM 2023) — over 17,000 patients followed for up to 5 years with reassuring cardiovascular and safety outcomes. Longer-term effects beyond 5 years are still being studied. The known long-term concerns are muscle/bone loss, gallbladder disease, and — if discontinued — weight regain.

What's the difference between Wegovy and compounded semaglutide?

Wegovy is the branded, FDA-approved version. Compounded semaglutide is made by compounding pharmacies, often during shortages, and is not FDA-approved. As of late 2024, the FDA declared the semaglutide shortage resolved, which limits the legal basis for compounding. Quality, purity, and dosing accuracy of compounded products vary — prefer the branded product when accessible.

The Bottom Line

Wegovy works. A 14.9% mean body weight reduction over 68 weeks (STEP-1) is pharmacological territory weight loss drugs have never reached before. But Wegovy is semaglutide dosed up, and the higher dose produces proportionally more side effects — particularly in the gut, and particularly in the first three months.

Most side effects are manageable with the playbook above: slow dose escalation, protein-first eating, electrolyte hydration, fiber, ginger, and targeted supplementation. The harder-to-manage issues — muscle loss, hair thinning, "Wegovy face," and especially weight regain after stopping — require active nutritional strategy from day one, not damage control at month six.

Take our 2-minute GLP-1 quiz to get a side-effect-matched supplement protocol based on your dose, starting weight, and symptoms. Or browse the SQ[1] GLP-1 shop for the muscle, hair, and nutrient-support stacks formulated for people on semaglutide.

Sources

• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). New England Journal of Medicine. 2021;384:989–1002.
• Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP-4). JAMA. 2021;325(14):1414–1425.
• Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016;375:1834–1844.
• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). New England Journal of Medicine. 2023;389:2221–2232.
• Prado CM, et al. Muscle matters: the effects of medically induced weight loss on skeletal muscle. The Lancet Diabetes & Endocrinology. 2024;12(11):785–787.
• U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information. Updated 2024.
• U.S. Food and Drug Administration. Drug Safety Communication: Gallbladder warning added to Wegovy labeling. March 2022.
• American College of Lifestyle Medicine and American Society for Nutrition. Joint Advisory on Nutritional Considerations in GLP-1 Therapy. 2025.

Medical Advisor Disclaimer

This article is for educational purposes and does not constitute medical advice. Wegovy is a prescription medication with a boxed warning; treatment decisions, dose adjustments, and supplement protocols should be made in partnership with a licensed healthcare provider familiar with your medical history. Discontinue Wegovy and seek immediate medical attention for severe abdominal pain, persistent vomiting, signs of allergic reaction, or any symptom you believe may be serious. SQ[1] products are dietary supplements and are not intended to diagnose, treat, cure, or prevent any disease. Content reviewed by the SQ[1] Medical Advisory Board; last updated April 2026.